Back to Search
Start Over
Sativex in the management of multiple sclerosis-related spasticity: An overview of the last decade of clinical evaluation
- Source :
- Multiple Sclerosis and Related Disorders; October 2017, Vol. 17 Issue: 1 p22-31, 10p
- Publication Year :
- 2017
-
Abstract
- Spasticity is a common symptom of multiple sclerosis (MS) affecting about 80% of MS patients. Numerous lines of evidence suggest that spasticity due to its complexity is not adequately managed with conventional anti-spastic therapies. Therefore, in order to improve the outcomes for the majority of MS patients, alternative approaches are needed to be discovered. Over the last years, the use of cannabinoid compounds as a potential treatment for MS-related symptoms has aroused great interest, owing to encouraging preclinical and clinical studies. To date, Sativex, an oromucosal spray containing tetrahydrocannabinol and cannabidiol in approximately 1:1 ratio, is the only commercially available formulation containing cannabinoids used as add-on therapy for treatment of spasticity in adult MS patients who are not responding to conventional antispastic therapies.
Details
- Language :
- English
- ISSN :
- 22110348
- Volume :
- 17
- Issue :
- 1
- Database :
- Supplemental Index
- Journal :
- Multiple Sclerosis and Related Disorders
- Publication Type :
- Periodical
- Accession number :
- ejs42641781
- Full Text :
- https://doi.org/10.1016/j.msard.2017.06.015